Developments for LDT Regulation and Laboratory Reimbursement: Bill Morice, M.D., Ph.D.


Answers From the Lab

Published October 16, 2025

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, discuss recent regulatory and policy developments. Together, they explore:

  • FDA rescinds rule on LDTs (00:48): The FDA has officially withdrawn its rule that would allow oversight of laboratory-developed tests (LDTs) as medical devices. The conversation explores what this decision means and what might come next for LDT regulation.
  • PAMA reform update and new RESULTS Act (05:13): The newly introduced Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act aims to address reimbursement for laboratory tests.
  • Getting engaged (12:37): Why it is important to understand new regulatory policies and help others understand their implications for the industry.

Resources

Podcast episode

Note: Information in this post was accurate at the time of its posting.

Podcast episode in video format

Jessie Fenske

Jessie Fenske is a senior marketing specialist at Mayo Clinic Laboratories. She joined Mayo Clinic in 2010 and enjoys partnering with patients and employees to share their stories of innovation, persistence and hope.